Maxine Gowen

Insider profile

Currently holds positions in Idera Pharmaceuticals Inc, Trevena Inc and Akebia Therapeutics Inc

Performance

Overall performance
3.2
Performance over holding periods
3.2
30 days 90 days 120 days
Average return 47% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
1 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Director Idera Pharmaceuticals Inc Jan. 4, 2016 -
Director Trevena Inc Oct. 1, 2018 -
Independent Director Akebia Therapeutics Inc July 28, 2014 -
President, Chief Executive Officer, Director Trevena Inc None -
Independent Director Human Genome Sciences Inc Feb. 15, 2008 - July 30, 2012
Maxine Gowen's trades of Idera Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
496.46
Quantity 58,926
Value US$1,988,208
Transaction date
Planned sale
Price
203.27
Quantity 48,668 +29.2%
Value US$4,302,338
US Trevena Inc (TRVN)
Transaction date
Purchase
Price
1.02
Quantity 50,000 +1250.0%
Value US$51,000
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2023-08-11 2023-08-10
S Sale
5,054 -40.5%
52.26
US$420,721 		5,054 -40.5% 52.26 US$420,721
2023-08-10 2023-08-10
PrS Proposed sale
58,926
496.46
US$1,988,208 		58,926 496.46 US$1,988,208
2020-06-09 2020-06-08
PlS Planned sale
48,668 +29.2%
203.27
US$4,302,338 		48,668 +29.2% 203.27 US$4,302,338
2019-02-05 2019-02-01
US Trevena Inc (TRVN)
B Purchase
50,000 +1250.0%
1.02
US$51,000 		50,000 +1250.0% 1.02 US$51,000